COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203

We read with interest the comments by Javeria Malik and Laksh Kumar1 on our published article “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”.2 We acknowledge their appreciation of the fact that this work primarily aimed to address an important gap in evidence related to the use of beta-blocker therapy in heart failure with preserved ejection fraction (HFpEF). We hereby wish to re-emphasize that although this article is classified as a narrative review, we performed a comprehensive literature search using MEDLINE and EMBASE databases (through Ovid interface) and utlizing broad key terms, without conducting a systematic review. Although the narrative reviews explicitly recognize that they may not include all relevant literature on a topic,3 we included all the studies that complied with our intended goal or main inclusion criterion, i.e., review of studies that enrolled patients with left ventricular ejection fraction (LVEF) according to the current definition of 50% or above. However, it was realized that many studies recruited patients with LVEF >40%, hence we opted to only consider the studies where the mean LVEF was 50% or above.

Other Information

Published in: Current Problems in Cardiology
License: http://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.1016/j.cpcardiol.2024.102379